Mitogen-activated lymphocytes: A good model for characterising lung CYP1A1 inducibility

被引:11
作者
Jacquet, M [1 ]
Lambert, V [1 ]
Todaro, A [1 ]
Kremers, P [1 ]
机构
[1] CHU SART TILMAN,SERV CHIM MED,B-4000 LIEGE,BELGIUM
关键词
CYP1A1; lung cancer; lymphocyte;
D O I
10.1023/A:1007354532547
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The CYP1A1 hyperinducibility phenotype occurring in some 10% of the human population corresponds to a higher risk of developing lung cancer. This study was undertaken to assess whether the inducibility factor, generally evaluated on mitogen-activated lymphocytes after PAH induction, represents correctly the lung situation. Optimal experimental conditions were determined for evaluating, on both lymphocytes and lung tissue explants, the inducibility factor, defined as the ratio of EROD activity (CYP1A1-specific) to cytochrome c reductase activity (unaffected by PAH induction). Paired results for lymphocytes and lung tissue samples from 10 lung cancer patients were compared. A good correlation was observed between lymphocyte and lung tissue inducibilities (R = 0.809; p = 0.005). In conclusion, mitogen-activated lymphocyte inducibility is indicative of lung tissue inducibility and constitutes a good marker for evaluating individual PAH inducibilities.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 28 条
[1]   GENETIC SUSCEPTIBILITY TO LUNG-CANCER WITH SPECIAL EMPHASIS ON CYP1A1 AND GSTM1 - A STUDY ON HOST FACTORS IN RELATION TO AGE AT ONSET, GENDER AND HISTOLOGICAL CANCER TYPES [J].
ALEXANDRIE, AK ;
SUNDBERG, MI ;
SEIDEGARD, J ;
TORNLING, G ;
RANNUG, A .
CARCINOGENESIS, 1994, 15 (09) :1785-1790
[2]   SMOKING AND PERIPHERAL TYPE OF CANCER ARE RELATED TO HIGH-LEVELS OF PULMONARY CYTOCHROME-P450IA IN LUNG-CANCER PATIENTS [J].
ANTTILA, S ;
HIETANEN, E ;
VAINIO, H ;
CAMUS, AM ;
GELBOIN, HV ;
PARK, SS ;
HEIKKILA, L ;
KARJALAINEN, A ;
BARTSCH, H .
INTERNATIONAL JOURNAL OF CANCER, 1991, 47 (05) :681-685
[3]  
BURKE MD, 1974, DRUG METAB DISPOS, V2, P583
[4]   GENETIC-POLYMORPHISM OF INDUCTION OF CYP1A1 (EROD) ACTIVITY [J].
CATTEAU, A ;
DOURIEZ, E ;
BEAUNE, P ;
POISSON, N ;
BONAITIPELLIE, C ;
LAURENT, P .
PHARMACOGENETICS, 1995, 5 (02) :110-119
[5]   A NOVEL CYP1A1 GENE POLYMORPHISM IN AFRICAN-AMERICANS [J].
CROFTS, F ;
COSMA, GN ;
CURRIE, D ;
TAIOLI, E ;
TONIOLO, P ;
GARTE, SJ .
CARCINOGENESIS, 1993, 14 (09) :1729-1731
[6]   RESPIRATORY-TRACT UPTAKE OF INHALANTS AND METABOLISM OF XENOBIOTICS [J].
DAHL, AR ;
LEWIS, JL .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1993, 33 :383-407
[7]  
DOURIEZ E, 1993, THESIS U PARIS 5
[8]  
DRAKOULIS N, 1994, CLIN INVESTIGATOR, V72, P240
[9]   Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence [J].
Jacquet, M ;
Lambert, V ;
Baudoux, E ;
Muller, M ;
Kremers, P ;
Gielen, J .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (10) :1701-1706
[10]   ARYL-HYDROCARBON HYDROXYLASE IN LYMPHOCYTES AND LUNG-TISSUE FROM LUNG-CANCER PATIENTS AND CONTROLS [J].
KARKI, NT ;
POKELA, R ;
NUUTINEN, L ;
PELKONEN, O .
INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (05) :565-570